Publication: The Efficacy and Safety of Gliquidone in Thai Diabetics
Issued Date
1997-12-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-0031451660
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.80, No.12 (1997), 771-776
Suggested Citation
Wannee Nitiyanant, Sutin Sriussadaporn, Chaicharn Deerochanawong, Supannee Ngawngamrat, Yupin Benjasuratwong, Somchai Patanaungkul The Efficacy and Safety of Gliquidone in Thai Diabetics. Journal of the Medical Association of Thailand. Vol.80, No.12 (1997), 771-776. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/18049
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The Efficacy and Safety of Gliquidone in Thai Diabetics
Other Contributor(s)
Abstract
This study was aimed to evaluate the efficacy and safety of gliquidone, the lastest available sulphonylurea, as a monotherapy for patients with non-insulin dependent diabetes millitus (NIDDM). Ninety patients attending diabetic clinics of Siriraj, Rajavithi and Pramongkutklao Army Hospitals were recruited in study. They were 21 males and 69 females, 27-82 years old (mean±SD = 52.3±11.2 years). The diabetic duration varied from newly diagnosed to 18 years (mean±SD = 1.5±2.8 years). Four weeks washout period was applied to 40 patients who had been treated with oral hypoglycemic agents. Before initiation of therapy, fasting venous blood samples were obtained for determination of fasting plasma glucose (FPG), Hemoglobin A1 (HbA1), lipid profile, chemistry profile and complete blood count (CBC). The starting dose of gliquidone was 15-60 mg by mouth once or twice daily. The dosage was adjusted every 4 weeks. FPG, HbA1 and lipid profile were assessed every 4 weeks. Blood chemistry profile and CBC were monitored at 4 weeks after treatment and at the end. After 12 weeks of therapy, FPG and HbA1 significantly declined from 220.8±55.5 mg/dl and 11.3±2.6 per cent to 159.1±38.6 mg/dl and 9.2± 1.4 per cent, respectively (p<0.001). A small but statistically significant decrease in serum total cholesterol from 229.3±46.9 to 219.8±40.7 mg/dl (p<0.01) as well as serum low density lipoprotein cholesterol from 150.2±43.7 to 142.2±42.1 mg/dl (p<0.05) were observed. Serum triglyceride and high density lipoprotien cholesterol did not significantly alter. Clinical follow-up, blood chemistry profile and CBC did not indicate any adverse reactions from gliquidone therapy. We concluded that gliquidone is an effective oral hypoglycemic agent for treating patients with NIDDM. Adverse effects were not experienced by this group of patients.